Overview

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2023-03-17
Target enrollment:
Participant gender:
Summary
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Advaxis, Inc.
Treatments:
Pembrolizumab